LV11325B - Squalene synthetase inhibitors - Google Patents

Squalene synthetase inhibitors Download PDF

Info

Publication number
LV11325B
LV11325B LVP-95-379A LV950379A LV11325B LV 11325 B LV11325 B LV 11325B LV 950379 A LV950379 A LV 950379A LV 11325 B LV11325 B LV 11325B
Authority
LV
Latvia
Prior art keywords
compound
oxo
neopentyl
trans
tetrahydro
Prior art date
Application number
LVP-95-379A
Other languages
English (en)
Latvian (lv)
Other versions
LV11325A (lv
Inventor
Ernest S Hamanaka
Joel M Hawkins
Cheryl M Hayward
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of LV11325A publication Critical patent/LV11325A/xx
Publication of LV11325B publication Critical patent/LV11325B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • C07D267/08Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • C07D267/08Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
LVP-95-379A 1994-12-23 1995-12-21 Squalene synthetase inhibitors LV11325B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36271394A 1994-12-23 1994-12-23
PCT/IB1995/000424 WO1996020184A1 (en) 1994-12-23 1995-06-02 Naphthyl-benzoxazepines or -benzothiazepines as squalene synthetase inhibitors

Publications (2)

Publication Number Publication Date
LV11325A LV11325A (lv) 1996-06-20
LV11325B true LV11325B (en) 1997-02-20

Family

ID=23427229

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-95-379A LV11325B (en) 1994-12-23 1995-12-21 Squalene synthetase inhibitors

Country Status (26)

Country Link
US (1) US5770594A (sv)
JP (1) JPH10500702A (sv)
KR (1) KR960022510A (sv)
CN (1) CN1133287A (sv)
AU (1) AU4067795A (sv)
BG (1) BG100248A (sv)
BR (1) BR9505995A (sv)
CA (1) CA2207772A1 (sv)
CZ (1) CZ344795A3 (sv)
FI (1) FI972696A (sv)
GT (1) GT199500058A (sv)
HU (1) HUT74672A (sv)
IL (1) IL116399A0 (sv)
IS (1) IS4312A (sv)
LV (1) LV11325B (sv)
MA (1) MA23746A1 (sv)
MX (1) MX9704683A (sv)
NO (1) NO955288L (sv)
OA (1) OA10204A (sv)
PE (1) PE60096A1 (sv)
PL (1) PL311997A1 (sv)
SI (1) SI9500393A (sv)
SK (1) SK158795A3 (sv)
TN (1) TNSN95133A1 (sv)
TR (1) TR199501644A2 (sv)
WO (1) WO1996020184A1 (sv)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965553A (en) * 1996-06-20 1999-10-12 Pfizer Inc. Squalene synthetase inhibitors
WO1997048701A1 (en) * 1996-06-20 1997-12-24 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US6403576B1 (en) * 1998-08-24 2002-06-11 The United States Of America As Represented By The Secretary Of The Navy Antifungal and antiparasitic compounds
US20020054871A1 (en) * 1999-04-12 2002-05-09 Yadong Huang Methods and compositions for use in the treatment of hyperlipidemia
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
EP1225880A2 (en) * 1999-11-04 2002-07-31 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders
AU2002214056A1 (en) 2000-11-21 2002-06-03 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
WO2008121602A1 (en) * 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
GB0803747D0 (en) * 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332792T2 (de) * 1992-04-20 2004-01-15 Takeda Chemical Industries Ltd 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
JPH09511753A (ja) * 1994-09-20 1997-11-25 ファイザー・インコーポレーテッド コレステロール吸収阻害薬とコレステロール合成阻害薬の併用

Also Published As

Publication number Publication date
NO955288L (no) 1996-06-24
BG100248A (en) 1996-07-31
CN1133287A (zh) 1996-10-16
PE60096A1 (es) 1996-12-28
HUT74672A (en) 1997-01-28
MA23746A1 (fr) 1996-07-01
WO1996020184A1 (en) 1996-07-04
FI972696A0 (sv) 1997-06-23
TR199501644A2 (tr) 1996-11-21
TNSN95133A1 (fr) 1996-02-06
SI9500393A (en) 1997-04-30
CZ344795A3 (en) 1996-09-11
KR960022510A (ko) 1996-07-18
NO955288D0 (no) 1995-12-22
GT199500058A (es) 1997-06-05
IL116399A0 (en) 1996-03-31
HU9503783D0 (en) 1996-04-29
MX9704683A (es) 1997-09-30
CA2207772A1 (en) 1996-07-04
IS4312A (is) 1996-06-24
FI972696A (sv) 1997-06-23
LV11325A (lv) 1996-06-20
PL311997A1 (en) 1996-06-24
OA10204A (en) 1996-12-18
BR9505995A (pt) 1997-12-23
US5770594A (en) 1998-06-23
JPH10500702A (ja) 1998-01-20
SK158795A3 (en) 1997-01-08
AU4067795A (en) 1996-07-04

Similar Documents

Publication Publication Date Title
US7829597B2 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
JP5203361B2 (ja) プロリルヒドロキシラーゼ阻害剤
JP6325449B2 (ja) シクロプロパンアミン化合物およびその用途
ES2384309T3 (es) Derivados de ácido carboxílico sustituidos de manera oxo-heterocíclica y su uso
US6677333B1 (en) 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient
US6537987B1 (en) 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
US5965553A (en) Squalene synthetase inhibitors
JP4944286B1 (ja) シクロプロパン化合物
US7820674B2 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
US20160058768A1 (en) Substituted amide compounds
BRPI0806566A2 (pt) Derivados de glicina n-substituída: inibidores de hidroxilase
CA2450475A1 (en) Dipeptidyl peptidase inhibitors for the treatment of diabetes
JP2009543790A (ja) 2−置換プロリンビス−アミドオレキシン受容体アンタゴニスト
OA11663A (en) Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors recptors (antipsychotic agents).
JP2012506378A (ja) 2,3−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト
JP6757336B2 (ja) 新規なジフルオロケトアミド誘導体
EA015813B1 (ru) Замещенные производные оксадиазола в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
US5770594A (en) Naphthyl-benzoxazepines or -benzothiazepines as squalene synthetase inhibitors
JP2011506466A (ja) カルボキサミド化合物ならびにケモカイン受容体アゴニストとしてのそれらの使用
JP2009503106A (ja) アミノエタンスルホンアミドオレキシン受容体アンタゴニスト
EA008928B1 (ru) Активаторы рецепторов, активируемых пролифератором пероксисом (ppar )
EA036137B1 (ru) Производные тетрагидроизохинолина
JPH09506371A (ja) 神経伝達物質放出増強薬としての新規な非環式および環式アミド類
JP2019507176A (ja) Htra1阻害剤としての新規ジフルオロケタミド誘導体
Suh et al. Angiotensin-converting enzyme inhibitors. New orally active antihypertensive (mercaptoalkanoyl)-and [(acylthio) alkanoyl] glycine derivatives